Security key
04272N102
ArriVent BioPharma, Inc. - Common Stock (AVBP)
CUSIP: 04272N102
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 21,851,940
- Total 13F value
- $388,890,872
- Share change
- +21,825,391
- SEC-reported price per share
- $17.86
- Number of holders
- 53
- Value change
- +$388,416,714
- Number of buys
- 51
- Shares outstanding
- 46,795,294
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
53
Top holders
10
AVBP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
ArriVent BioPharma, Inc. SEC filings
ArriVent BioPharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 04272N102
Recent filing periods:
Ownership snapshot
Top reported holders of AVBP - ArriVent BioPharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Carl L. Gordon
Disclosed value leader
James Healy
Comparable rows
0/4
Latest evidence
30 Jan 2024
3/4/5
Highest disclosed value: $6,193,145
4 rows are not safely comparable across share classes.
Quick read
James Healy has the largest disclosed position value at $6.19M.
0 of 4 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens James Healy's linked filing trail.
Disclosed position value
Top 3
Carl L. Gordon
$5.52M
ORBIMED ADVISORS LLC
$5.52M
James Healy
$6.19M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-4 of 4 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Carl L. Gordon |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
$5,524,874
1,513,664 shares
|
— | 30 Jan 2024 |
| ORBIMED ADVISORS LLC |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
$5,524,874
1,513,664 shares
|
— | 30 Jan 2024 |
| James Healy |
3/4/5
Director
|
—
class O/S missing
|
$6,193,145
1,696,752 shares
|
— | 30 Jan 2024 |
| Jallal Bahija |
3/4/5
Director
|
—
class O/S missing
|
—
17,884 shares
|
— | 25 Jan 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
53
Shares
21,851,940
Rows available
53
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2024 Across Filers
Q1 2024 holders
53
Q1 2024 holders
53
Holder diff
0
| Investor | Q1 2024 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend